Treatment of cryptosporidiosis: nitazoxanide yes, but we can do better

• Published in: Expert review of anti-infective therapy Vol. 21; no. 2; p. 167
• Main Authors: Caravedo, Maria A, White, Jr, A Clinton
• Format: Journal Article
• Language: English
• Published: England 01-02-2023
• Subjects: Acquired Immunodeficiency Syndrome; Antiprotozoal Agents; Child; Child, Preschool; Cryptosporidiosis - drug therapy; Cryptosporidiosis - parasitology; Cryptosporidium; Diarrhea - drug therapy; Humans; nitazoxanide; Cryptosporidium; malnutrition; AIDS
• ISSN: 1744-8336
• DOI: 10.1080/14787210.2023.2160704

Cryptosporidiosis was initially recognized as an important cause of diarrhea in AIDS patients. It has been underdiagnosed in other populations. Recent studies have highlighted the importance of Cryptosporidium as a cause of diarrhea and malnutrition in young children in resource-poor countries and an emerging pathogen in organ-transplant recipients.
Nitazoxanide is FDA approved for treatment of cryptosporidiosis in immunocompetent people. However, it is less effective in HIV and transplant patients and malnourished children. In transplant recipients, there is emerging data on antiparasitic combinations for cryptosporidiosis, including combinations of nitazoxanide, azithromycin, and in one case rifaximin. High-throughput phenotypic screens have identified some potential treatments. Among them, clofazimine was no better than placebo in a trial in AIDS patients. There have also been efforts to develop drug versus specific parasite targets. However, in part due to safety issues, none of these compounds have advanced into clinical trials.
Development of new and more efficacious therapies for cryptosporidium is imperative. Current approve therapy is far from optimal and lacks efficacy in high-risk populations, such as, patients living with HIV. Additionally, there is limited data on patients with other types of immunosuppression (Transplanted, autoimmune conditions, etc).